Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferric Maltol vs FCM for IDA in IBD
NCT02680756Phase 3Completed
- Sponsor
- Shield Therapeutics plc
- Start
- Jan 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of ferric maltol in iron deficiency anemia (IDA), sponsored by Shield Therapeutics plc. Started Jan 2016; status: completed.
02
Drugs
ferric maltol
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT02680756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02680756.